TSX earnings scorecard: How third-quarter results have fared so far

Share

Globe editors have posted this research report with permission of Thomson Reuters I/B/E/S. This should not be construed as an endorsement of the report's recommendations. For more on The Globe's disclaimers please read here. The following is excerpted from the report:

The TSX Composite Earnings Scorecard is the most comprehensive and up-to-the-minute compilation of aggregated earnings growth and market intelligence covering the companies included in the TSX Composite Index. This report combines Thomson Reuters' unrivaled historical earnings database, in-depth coverage of sell-side analysts' bottom-up corporate earnings estimates, and the analytic capabilities of Thomson Reuters Proprietary Research Group and desktop solutions.

EARNINGS HIGHLIGHTS

Q3 2017 Y/Y Blended Earnings Growth Estimates

• TSX Composite (.GSPTSE) = 11.6 per cent
• Ex-Energy = 6.8 per cent
• Valeant Pharmaceuticals International Inc. = -45.6 per cent
• Healthcare Ex- VRX = -37.8 per cent
• TSX Composite Ex-VRX = 12.7 per cent

Q3 2017 Performance vs. Earnings Expectations

Eleven per cent of the TSX Composite companies have reported Q3 2017 EPS. Of the 28 companies in the index that have reported earnings to date for Q3 2017:

• 60.7 per cent reported above analyst expectations
• 35.7 per cent reported below analyst expectations

Q4 2017 Y/Y Blended Earnings Growth Estimates

• TSX Composite = 13.1 per cent
• Ex-Energy = 11.7 per cent
• Valeant Pharmaceuticals = -30.9 per cent
• Healthcare Ex- VRX = -5.0 per cent
• TSX Composite Ex-VRX = 13.8 per cent

REVENUE HIGHLIGHTS

Q3 2017 Y/Y Blended Revenue Growth Estimates

• TSX Composite = 45.4 per cent
• Ex-Energy = 49.5 per cent
• Valeant Pharma. (VRX.TO) = -17.6 per cent
• Healthcare Ex-Valeant Pharma. = 11.8 per cent
• TSX Composite Ex-Valeant Pharma. = 46.1 per cent

Q3 2017 Performance vs. Revenue Expectations

Of the TSX Composite companies that have reported revenue to date for Q3 2017:

• 48.4 per cent reported above analyst expectations
• 51.6 per cent reported below analyst expectations

Q4 2017 Y/Y Blended Revenue Growth Estimates

• TSX Composite (.GSPTSE) = 14.8 per cent
• Ex-Energy = 13.3 per cent
• Valeant Pharmaceuticals = -14.9 per cent
• Healthcare Ex-Valeant Pharma = 11.0 per cent
• TSX Composite Ex-Valeant Pharma = 15.2 per cent

Click here to see a full copy of the Thomson Reuters I/B/E/S TSX Composite Earnings Scorecard.

Globe app users click here for the full report

Read other research reports here.